サンプル依頼リスト カート
  • English
  • Korean
表紙：地図状萎縮の世界市場-2023年～2030年
市場調査レポート
商品コード
1352176

地図状萎縮の世界市場-2023年～2030年

Global Geographic Atrophy Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.97円
地図状萎縮の世界市場-2023年～2030年
出版日: 2023年09月27日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

世界の地図状萎縮市場は2022年に185億米ドルに達し、2023-2030年の予測期間中にCAGR 7.2％で成長し、2030年には351億米ドルに達すると予測されています。

地図状萎縮市場は、疾患の有病率の増加、研究開発の増加、研究資金の増加、主要企業間の協力などの要因によって牽引されています。

地図状萎縮では、網膜の黄斑部が目の病気である黄斑変性症の影響を受けます。この疾患により、視力の中心が著しく損なわれます。周辺視野（中心部の両側に見えるもの）はまだ利用可能です。地図状萎縮は通常、両眼（両側）に発症します。地図状萎縮は、視野の中心に盲斑（暗点）を生じさせるとともに、鋭さの点で部分的な視力低下をもたらします。世界には800万人以上の地図状萎縮患者がいます。人口の約20％が加齢黄斑変性症です。

ダイナミクス

FDA認可の増加が世界地図状萎縮市場の成長を牽引

アステラス製薬の声明によると、2023年8月、FDAは加齢黄斑変性症（AMD）に続発する地図状萎縮（GA）の治療薬としてIZERVAY（avacincaptad pegol intravitreal solution）を承認しました。ライセンシングされたGA治療薬の中で、2つの第III相臨床試験において12ヶ月の主要評価項目でGA進行率を統計学的に有意に減少（p0.01）させた唯一の薬剤は、新規補体C5阻害剤であるIZERVAYです。

GATHER1およびGATHER2第3相臨床試験は、AMDに続発するGA患者を対象に、イゼルベイの月1回2mgの硝子体内投与の安全性と有効性を評価したもので、FDAの承認取得の基礎となっています。投与開始時、6ヵ月後、12ヵ月後にGAの成長率が評価されました。各登録試験の12ヵ月にわたる主要な解析の結果、偽治療と比較してイゼルベイの投与を受けた患者では、GAの増加速度が統計学的に有意に遅かったことが明らかになっています。

地図状萎縮の治療法を調査するための主要企業間の協力関係の増加が、世界の地図状萎縮市場の成長を後押しします

例えば、2023年2月、臨床段階のバイオテクノロジー企業であるRallybio Corporationは、重篤な希少疾患患者のための生命を変える治療法の特定と開発の加速に専念しており、また、EyePoint Pharmaceuticals, Inc.は、重篤な眼疾患患者の生活を改善するための治療薬の開発と商業化に専念している企業であり、共同研究を発表しました。

この共同研究では、アイポイント社独自のデュラサート技術を用いて、ラリーバイオ社の補体成分5（C5）阻害剤の持続的な眼内投与について評価します。不可逆的な視力低下を引き起こす加齢黄斑変性の進行型である地図状萎縮が最初の焦点となります。C5阻害剤の眼疾患治療への使用は大きな可能性を示しているため、彼らは、地図状萎縮のような眼疾患に苦しむ人々の生活を改善することを願って、この調査を開始することに興奮しています。

地図状萎縮の課題が世界地図状萎縮市場の成長を妨げる

これは、特にヘルスケア資源が乏しい遠隔地や低開発地域では深刻な問題となる可能性があります。眼科医へのアクセス不足により、眼疾患の特定と治療が困難になり、人々の視力や一般的な生活の質に影響を及ぼす可能性があります。目の病気に関する不確実性は、公衆衛生上の深刻な問題となり得ます。

治療せずに放置すれば、様々な眼病が視力低下などの問題を引き起こす可能性があります。一般的な目の病気やその危険因子、定期的な眼科検診の価値について人々の認識を高めることで、予防策を講じたり、必要に応じてすぐに治療を受けたりするようになるかもしれません。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 地図状萎縮治療に対するFDA承認の増加
    • 抑制要因
      • 地図状萎縮に関連する課題
    • 機会
      • 技術の進歩
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • アンメットニーズ
  • 規制分析

第6章 COVID-19分析

第7章 ロシア・ウクライナ戦争分析

第8章 人工知能分析

第9章 治療タイプ別

  • 薬物療法
    • ペグセタコプラン
  • AREDS2サプリメント
  • 植込み型小型望遠鏡（IMT）

第10章 年齢層別

  • 60歳以上
  • 75歳以上

第11章 エンドユーザー別

  • 病院
  • 専門クリニック
  • その他

第12章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第13章 競合情勢

  • 競合シナリオ
  • 製品ベンチマーク
  • 企業シェア分析
  • 主な発展と戦略

第14章 企業プロファイル

  • Apellis Pharmaceuticals, Inc.（米国）
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Iveric Bio（米国）
  • Alkeus Pharmaceuticals, Inc.（米国）
  • Allegro Ophthalmics, LLC（米国）
  • Stealth BioTherapeutics（ケイマン諸島）
  • Gyroscope Therapeutics Limited（英国）
  • Regenerative Patch Technologies, LLC（米国）
  • Hoffmann-La Roche AG（スイス）
  • Genentech, Inc.（米国）
  • NGM Biopharmaceuticals Inc.（米国）

第15章 企業概要付録

目次
Product Code: PH6945

Overview

The Global Geographic Atrophy Market reached US$ 18.5 billion in 2022 and is expected to reach US$ 35.1 billion by 2030 growing with a CAGR of 7.2% during the forecast period 2023-2030.

The Geographic Atrophy market is driven by factors such as increasing prevalence of the disease, increasing research and development, rising funding for research, and collaboration among key players.

In Geographic Atrophy, the macula of the retina is impacted by the eye ailment macular degeneration. The center of vision is severely impaired by this condition. The peripheral vision-what we can see on the sides of the center-will still be available. Geographic atrophy typically affects both eyes (bilaterally). Geographic atrophy causes blind patches (scotoma) in the center of vision as well as partial vision loss in terms of sharpness. There are more than 8 million geographic atrophy sufferers worldwide. About 20% of the population has age-related macular degeneration.

Dynamics

The Increasing FDA Approval is Driving the Global Geographic Atrophy Market Growth

In August 2023, the FDA authorized IZERVAY (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) according to a statement from Astellas Pharma Inc. The only licensed GA medication showing a statistically significant decrease (p0.01) in the rate of GA progression at the 12-month primary objective across two Phase 3 clinical trials is IZERVAY, a novel complement C5 inhibitor.

The GATHER1 and GATHER2 Phase 3 clinical trials, which assessed the safety and effectiveness of monthly 2 mg intravitreal administration of IZERVAY in patients with GA secondary to AMD, served as the foundation for the FDA's clearance. In the beginning, six months, and twelve months, the GA growth rate was assessed. The major analysis of each registrational trial over a 12-month period revealed that patients who received IZERVAY as opposed to sham treatment experienced a statistically significant slower rate of GA increase.

The Increasing Collaboration Among Key Players to Research Treatment for Geographic Atrophy Boosts the Global Geographic Atrophy Market Growth

For instance, in February 2023, Rallybio Corporation, a clinical-stage biotechnology company dedicated to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, and EyePoint Pharmaceuticals, Inc., a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, announced a research collaboration.

The collaboration will assess the sustained intraocular medication delivery of Rallybio's inhibitor of complement component 5 (C5) using EyePoint's exclusive Durasert technology. Geographic atrophy, an advanced form of age-related macular degeneration that causes irreversible visual loss, will be the initial focus. They are thrilled to start this research in the hopes of bettering the lives of people suffering from eye illnesses like geographic atrophy because the use of C5 inhibitors for the treatment of eye disease has shown significant potential.

Challenges with Geographic Atrophy are Hampering the Global Geographic Atrophy Market Growth

This can be a serious problem, especially in remote or underdeveloped locations with scarce healthcare resources. Lack of access to eye doctors can make it challenging to identify and treat eye diseases, which could have an impact on people's vision and general quality of life. Uncertainty about eye illnesses can be a serious public health issue.

If left untreated, a variety of eye diseases can result in issues like vision loss. Increasing people's awareness of common eye conditions, their risk factors, and the value of routine eye exams might encourage people to adopt preventative measures and seek treatment as soon as necessary.

Segment Analysis

The global geographic atrophy market is segmented based on treatment type, age group, end user, and region.

The AREDS2 supplements Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period

The AREDS2 supplements segment accounted for the highest market stake accounting for approximately 45.2% of the geographic atrophy market in 2022.

The National Eye Institute (NEI) in the United States undertook the AREDS2 study (Age-Related Eye Disease Study 2) to test the impact of dietary supplements on the progression of age-related macular degeneration (AMD). One type of AMD is geographic atrophy, commonly referred to as atrophic or dry AMD.

These antioxidant-rich supplements underwent testing as part of the Age-Related Eye Disease Study. These are used by certain medical professionals to treat dry age-related macular degeneration. The same components are included in an AREDS1 formula together with beta-carotene. However, beta-carotene has been linked to lung cancer among smokers. Lutein, zeaxanthin, vitamin E, zinc oxide, and cupric oxide are all components of AREDS2.

The findings of the AREDS2 trial revealed that the modified AREDS2 formulation, which reduced the zinc dose and replaced beta-carotene with lutein and zeaxanthin, was equally as beneficial in lowering the risk of AMD progression as the original AREDS formulation.

Geographical Penetration

North America Holds a Dominant Position in the Global Geographic Atrophy Market

North America is estimated to hold around 1/3rd of the total market share throughout the forecast period. In July 2023, Apellis Pharmaceuticals, Inc. reported that Geographic atrophy (GA), a complication of age-related macular degeneration (AMD), was treated in real-world settings with SYFOVRE (pegcetacoplan injection).

These incidents are still extremely uncommon even after 68,000 commercial vials have been delivered and 23,000 clinical trial injections. Additionally, during the course of their ongoing assessment, they found no evidence that problems with the manufacturing or drug product may have led to these incidents. The company will keep working with the retinal community to provide a secure, efficient remedy for geographic atrophy.

Competitive Landscape

The major global players in the market include: Apellis Pharmaceuticals, Inc. (US), Iveric Bio (US), Alkeus Pharmaceuticals, Inc. (US), Allegro Ophthalmics, LLC (US), Stealth BioTherapeutics (Cayman Islands), Gyroscope Therapeutics Limited (UK), Regenerative Patch Technologies, LLC (US), Hoffmann-La Roche AG (Switzerland), Genentech, Inc. (US), and NGM Biopharmaceuticals Inc. (US) among others.

COVID-19 Impact Analysis

Russia-Ukraine Conflict Analysis

The Russia-Ukraine war may affect the geographic atrophy market due to a lack of facilities being impacted during times of geopolitical instability and economic uncertainty. Conflicts on the global stage can breed uncertainty and undermine investor confidence. Investor caution may prevail, which could have an impact on market funding, R&D, and development plans for geographic atrophy.

Artificial Intelligence Analysis:

Artificial intelligence (AI) is increasingly being used in the geographic atrophy market to improve various aspects of data analysis. Artificial intelligence may be able to forecast the progression of geographic atrophy in specific individuals, assisting clinicians in assessing the efficacy of medication therapy. If, as anticipated, medications in the pipeline are approved to delay the progression of the disease, accurate predictions will become crucial.

By Treatment Type

  • Medication
    • Pegcetacoplan
      • AREDS2 Supplements
      • Implantable Miniature Telescope (IMT)

By Age Group

  • Above 60 Years
  • Above 75 Years

By End Users

  • Hospitals
  • Specialty Clinics
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In February 2023, According to IVERIC bio, Inc., the FDA has completed its review of the company's New Drug Application (NDA) for avacincaptad pegol (ACP), a brand-new complement C5 inhibitor under investigation for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
  • In October 2022, NGM Biopharmaceuticals, Inc., biotechnology company reported topline efficacy and safety results from the randomized, double-masked, sham-controlled CATALINA Phase 2 trial of NGM621 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Why Purchase the Report?

  • To visualize the global geographic atrophy market segmentation based on the treatment type, age group, diagnosis, end user, and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of geographic atrophy market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of critical products of all the major players.

The global geographic atrophy market report would provide approximately 61 tables, 57 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Treatment Type
  • 3.2. Snippet by Age Group
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising FDA approval for Geographic Atrophy Treatment
    • 4.1.2. Restraints
      • 4.1.2.1. Challenges associated with Geographic Atrophy
    • 4.1.3. Opportunity
      • 4.1.3.1. Technological advancements
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Treatment Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.1.2. Market Attractiveness Index, By Treatment Type
  • 9.2. Medication*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 9.2.3. Pegcetacoplan
  • 9.3. AREDS2 Supplements
  • 9.4. Implantable Miniature Telescope (IMT)

10. By Age Group

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.1.2. Market Attractiveness Index, By Age Group
  • 10.2. Above 60 Years*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Above 75 Years

11. By End User

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.1.2. Market Attractiveness Index, By End User
  • 11.2. Hospitals*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Specialty Clinics
  • 11.4. Others

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.2.6.1. U.S.
      • 12.2.6.2. Canada
      • 12.2.6.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.3.6.1. Germany
      • 12.3.6.2. U.K.
      • 12.3.6.3. France
      • 12.3.6.4. Italy
      • 12.3.6.5. Spain
      • 12.3.6.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.4.6.1. Brazil
      • 12.4.6.2. Argentina
      • 12.4.6.3. Rest of South America
  • 12.5. Asia-Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.5.6.1. China
      • 12.5.6.2. India
      • 12.5.6.3. Japan
      • 12.5.6.4. Australia
      • 12.5.6.5. Rest of Asia-Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

13. Competitive Landscape

  • 13.1. Competitive Scenario
  • 13.2. Product Benchmarking
  • 13.3. Company Share Analysis
  • 13.4. Key Developments and Strategies

14. Company Profiles

  • 14.1. Apellis Pharmaceuticals, Inc. (US)*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Financial Overview
    • 14.1.4. Key Developments
  • 14.2. Iveric Bio (US)
  • 14.3. Alkeus Pharmaceuticals, Inc. (US)
  • 14.4. Allegro Ophthalmics, LLC (US)
  • 14.5. Stealth BioTherapeutics (Cayman Islands)
  • 14.6. Gyroscope Therapeutics Limited (UK)
  • 14.7. Regenerative Patch Technologies, LLC (US)
  • 14.8. Hoffmann-La Roche AG (Switzerland)
  • 14.9. Genentech, Inc. (US)
  • 14.10. NGM Biopharmaceuticals Inc. (US)

LIST NOT EXHAUSTIVE

15. Appendix

  • 15.1. About Us and Services
  • 15.2. Contact Us